DIFLUPREDNATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFLUPREDNATE (DIFLUPREDNATE).
Difluprednate is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators.
| Metabolism | Primarily hepatic via CYP450 enzymes, with major metabolite being 6α-fluoroprednisolone acetate. |
| Excretion | Primarily renal (65–75% as metabolites), with biliary/fecal excretion accounting for 15–25%. |
| Half-life | Terminal elimination half-life approximately 2–4 hours; clinically, duration of action may extend due to receptor binding. |
| Protein binding | Approximately 90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Approximately 0.5–0.8 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<5%); ophthalmic: <1% systemic bioavailability. |
| Onset of Action | Topical: within 2–3 hours for anti-inflammatory effect; ophthalmic: within 1–2 hours. |
| Duration of Action | Topical: 6–12 hours; ophthalmic: 4–8 hours depending on formulation and condition. |
Topical: Apply thin film to affected area twice daily.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Apply thin film to affected area once or twice daily; limit use to smallest amount for shortest duration. |
| Geriatric use | Use with caution due to increased risk of skin atrophy; apply smallest amount for shortest duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIFLUPREDNATE (DIFLUPREDNATE).
| Breastfeeding | No data on difluprednate in human milk. Systemic absorption after ophthalmic use is minimal; however, due to potential adverse effects, caution is advised. M/P ratio not available. |
| Teratogenic Risk | Difluprednate is a corticosteroid; systemic exposure is low with ophthalmic use. No adequate human studies. Animal studies show teratogenicity at high doses. FDA Pregnancy Category C. Theoretical risk of cleft palate if used in first trimester; avoid systemic absorption. Use only if potential benefit justifies risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to difluprednate or any component of the formulation","Active ocular infections (viral, bacterial, fungal, mycobacterial)","Corneal epithelial herpes simplex (dendritic keratitis)"]
| Precautions | ["Increased intraocular pressure (IOP) with prolonged use","Risk of posterior subcapsular cataract formation","Delayed wound healing","Increased susceptibility to ocular infections (including fungal) and exacerbation of existing infections","Potential for corneal thinning and perforation","Adrenal suppression with systemic absorption"] |
Loading safety data…
| Fetal Monitoring |
| Monitor intraocular pressure (IOP) regularly; corticosteroids may increase IOP. Monitor for cataract formation, secondary infection, and delayed wound healing. No specific fetal monitoring required due to low systemic absorption. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted specifically for difluprednate. Corticosteroids may affect hormonal balance; consider potential for menstrual irregularities or reduced fertility. |